Clinical development, evidence and the future of pharmaceutical R&D
I am a clinical development operations and portfolio leader with more than 20 years of experience across pharmaceutical, biotechnology and CRO organizations.
My work has covered global clinical operations, portfolio governance, program delivery, resource planning, CRO and vendor management, Real-World Evidence and Medical Affairs.
Across my career, I have managed international portfolios involving 64 countries, budgets of approximately US$25 million and multidisciplinary teams of more than 55 professionals.
Why this site exists
Artificial intelligence is changing how pharmaceutical companies discover medicines, design development programs, generate evidence and work with CROs and other partners. But technology alone does not resolve fragmented processes, weak evidence or unclear decisions.
This site is an independent space for evidence-based analysis of the changes shaping pharmaceutical R&D and clinical development—from AI and regulation to operational strategy, leadership and the value of professional experience.
Main areas of analysis
- Artificial intelligence in pharmaceutical R&D
- Clinical development, CROs and research operations
- Regulation, evidence quality and AI governance
- Leadership, the future of work and professionals over 50
The analyses and opinions published here are personal and do not represent any current or former employer or client.